Access to Market

Access to the market in the pharmaceutical industry refers to identifying, evaluating, and taking advantage of market opportunities to effectively and profitably launch innovative pharmaceutical products. This process involves business development strategies, such as technology acquisition, investment in research and development, and collaboration with partners. Pricing strategies can also be implemented, effective distribution channels can be selected, and marketing campaigns can be created that target the target market's specific needs. Access to the market for a pharmaceutical company can be a significant challenge, as the pharmaceutical market is highly regulated and competitive. The cost of developing and marketing new drugs can also be extremely high. Bringing a new drug to market costs approximately $2.6 billion (1). In addition, the processes for approval of new drugs by regulatory entities can be tedious and costly. The approval process for a new drug by the FDA is estimated to take 8 to 12 years (2).

Size of the Problem

• The average cost of bringing a pharmaceutical asset to market has reached $2 billion (1). However, over one-third (36%) of all new launches in the United States do not meet expectations (2).
• Half (50%) of the failures in drug launches in the United States were attributed to limited market access, followed by inadequate market understanding and customer needs (46%) and poor product differentiation (44%) (3).

Several significant issues affect access to the market in the pharmaceutical industry. Some of the most pronounced include:

■ High costs of development and regulation: The pharmaceutical industry faces high costs in researching, developing, and approving new products. These costs can be passed on to drug prices, limiting patient access (3).
■ Regulatory barriers: Regulation of pharmaceutical products can vary significantly in different countries and regions, which can delay market access and increase costs (4).
■ Lack of access to healthcare: In some countries and regions, access to healthcare is limited or nonexistent, making it difficult for patients to receive the needed medications (2).
■ Changes in public health policy: Public health policies can change, affecting medication coverage and availability in the market (5).
■ Competition from generic products: Once the patent on an innovative drug expires, generic products that compete on price may appear, limiting access to original medications (3).

‍

1. Research and Development: AI can significantly lower costs in the pharmaceutical industry by pinpointing potential molecules and compounds and refining the design of clinical trials. It also enhances the prediction of safety and efficiency for new products, thus expediting their approval and harmonizing regulatory standards across diverse regions, as shown in [1].

2. Healthcare Access and Treatment Improvement: AI plays a pivotal role in enhancing disease detection and treatment modalities, minimizing the necessity for costly medications. It extends improved healthcare access to remote and under-resourced locales, offering crucial adaptations in times of shifting public health policies. AI's capabilities also extend to optimizing pharmaceutical production and pricing models, and spearheading the development of novel products and services that create a clear distinction between innovative drugs and generic alternatives [2].
3. Pharmaceutical Market Analytics Assistant: This project involves developing a pharmaceutical market intelligence assistant trained to analyze data, identify market gaps, and suggest customized product development and marketing strategies. The assistant was developed using comprehensive datasets extracted from global pharmaceutical sales, demographic health surveys, and epidemiologic studies, [6, 7]. The assistant evaluates the data to determine market opportunities, suggest efficient distribution networks and creates targeted marketing strategies to cater to the diverse needs of Colombian populations. This initiative supports pharmaceutical companies in launching precisely targeted products that resonate with the localized demand and comply with the regional regulatory environments.

‍

• Prescription data: includes information on the amount and frequency of prescription drugs in different geographic regions, hospitals, clinics, doctors, and medical specialties. This data can help pharmaceutical companies understand market demand and physician and patient preferences better.
• Sales data: includes information on the revenue and market share of different medications and pharmaceutical products. This data can help pharmaceutical companies identify growth opportunities and optimize their pricing and marketing strategy.
• Clinical trial data: Includes information about the results of clinical trials, the patients involved, the doses used, and the observed side effects. This data can help pharmaceutical companies better understand the effectiveness and safety of their products and identify possible opportunities for research and development.
• Patent data: Includes information about granted and pending patents for different drugs and pharmaceutical products. This data can help pharmaceutical companies protect their intellectual property and plan their market launch strategy.
• Demographic and public health data: Includes information about the population, disease rates, prevalence of risk factors, and patterns of healthcare in different geographic regions. This data can help pharmaceutical companies identify market opportunities and develop products tailored to the specific needs of different populations.

‍